BRIEF—New chief executive at EVOQ Therapeutics

Autoimmune disease specialist EVOQ Therapeutics has appointed David Giljohann as chief executive, replacing co-founder William Brinkerhoff, who has served as CEO since the company was established in 2016.

Dr Giljohann has over a decade of experience in the industry, and most recently served as chief executive at Exicure, where he led the company in developing spherical nucleic acid (SNA) constructs.

The Michigan, USA-based firm has also appointed Greg Barrett, president of the company since 2018, as chief operating officer.

Dr Giljohann said: “The pre-clinical efficacy demonstrated in multiple autoimmune diseases underscores the potential of EVOQ’s transformative immunotherapies.”

He added: “I’m thrilled to join EVOQ at such an exciting time and to lead the company as we continue executing on our milestones and advancing our NanoDisc platform technology.”